GRAIL to Announce Third Quarter 2026 Financial ResultsPRNewsWire · 3 days ago
GRAIL (NASDAQ:GRAL) Stock: Insider Joshua Ofman Sells 20,000 SharesDefense World · 6 days ago
GRAIL (NASDAQ:GRAL) Stock Price Down 5.6% on Insider SellingDefense World · 6 days ago
11 Stocks Most Likely to See a Short Squeeze RallySchaeffers Research · Oct 12, 2026
First-Class Amenity Kits Have Become Holy Grail CollectiblesWSJ · Oct 12, 2026
Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.The Motley Fool · Oct 11, 2026GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$2.66 | -$2.56 | Beat |
| May 5, 2026 | -$2.76 | -$2.29 | Beat |
| Feb 19, 2026 | -$3.33 | -$2.44 | Beat |
| Nov 12, 2025 | -$3.36 | -$2.46 | Beat |
| Aug 12, 2025 | -$3.14 | -$3.18 | Miss |
| May 13, 2025 | -$4.03 | -$3.10 | Beat |